André Choulika on gene editing: "If you marry yourself to a technology, you're doomed."
Gene editing plays a major role in next-gen CAR-T programs. And Cellectis can now boast of a patent that touches on a broad range of technologies that will come into play.
The U.S. patent office has issued patent number 9,458,439, protecting the work that Cellectis CEO (and scientist) André Choulika and Harvard Professor Richard C. Mulligan, one of the original pioneers in the gene therapy field, have accomplished.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
